
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx NV has received European Commission marketing authorization for its product vilobelimab (Gohibic) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS), indicating regulatory confidence in its clinical efficacy and safety. The treatment demonstrated a notable 23.9% relative reduction in 28-day all-cause mortality compared to placebo, coupled with a well-tolerated safety profile across various doses. Additionally, forecasts project a strong market performance with projected sales of $86 million in 2030, growing to $225 million by 2031, reflecting a solid revenue trajectory as the company advances its innovative therapies.
Bears say
InflaRx NV has reported a decrease in C5a levels from baseline, indicating some efficacy of its product candidate, vilobelimab; however, the overall clinical outcomes, such as the maximum HiSCR rate of 51.5%, are modest when compared to the placebo's 47.1%. The company is exploring partnerships and distribution options in Europe, which may mitigate cash burn but does not address underlying challenges in achieving competitive clinical results. Consequently, these factors contribute to a cautious outlook regarding the company's financial sustainability and market position moving forward.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares